钙化积分何时等同于二级预防?来自跨国CONFIRM注册研究的启示
在跨国CONFIRM注册研究中,比较无已知冠心病者按CAC积分分层与已确诊ASCVD者的ASCVD事件率。CAC>300者与已确诊ASCVD者的MACE、全因死亡、MACE+晚期血运重建及MI事件率均无统计学显著差异(均P>0.05),CAC<300者事件率明显较低。
要点
- CAC>300且无ASCVD病史者,其MACE及组分事件率与已确诊ASCVD者无统计学显著差异。
- CAC<300者事件率明显低于已确诊ASCVD者,风险分层需结合CAC具体数值。
- 该观察为无ASCVD病史但CAC升高者的二级预防治疗目标研究提供背景。
核心结论
- CAC积分>300的无ASCVD病史者,其MACE及其组分风险与已确诊ASCVD并接受治疗者相当;CAC<300者事件率明显较低。
研究设计与样本
- 跨国CONFIRM注册研究中的队列研究,纳入4,511例无已知冠心病者与438例已确诊ASCVD者,比较按CAC积分(0、1–100、101–300、>300)分层的ASCVD事件率。
诊断标准与关键数值
- CAC积分分为0、1–100、101–300和>300四组;CAC>300组与已确诊ASCVD组的全因死亡、MACE、MACE+晚期血运重建及MI事件率均无统计学显著差异(均P>0.05);CAC<300组事件率明显较低。
临床应用与阅片要点
- 阅片报告CAC积分时,>300可作为与已确诊ASCVD风险相当的分层阈值,供临床评估预防干预强度参考。
局限性
- 原文结论指出,该观察为进一步研究无ASCVD病史但CAC升高者的二级预防治疗目标提供了重要背景。
- 原文结论指出,理解与稳定二级预防人群ASCVD风险相当的CAC积分,可能对更广泛地指导预防干预强度具有重要意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Elevated coronary artery calcium (CAC) scores in subjects without prior atherosclerotic cardiovascular disease (ASCVD) have been shown to be associated with increased cardiovascular risk.
OBJECTIVES: The authors sought to determine at what level individuals with elevated CAC scores who have not had an ASCVD event should be treated as aggressively for cardiovascular risk factors as patients who have already survived an ASCVD event.
METHODS: The authors performed a cohort study comparing event rates of patients with established ASVCD to event rates in persons with no history of ASCVD and known calcium scores to ascertain at what level elevated CAC scores equate to risk associated with existing ASCVD. In the multinational CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry, the authors compared ASCVD event rates in persons without a history of myocardial infarction (MI) or revascularization (as categorized on CAC scores) to event rates in those with established ASCVD. They identified 4,511 individuals without known coronary artery disease (CAC) who were compared to 438 individuals with established ASCVD. CAC was categorized as 0, 1 to 100, 101 to 300, and >300. Cumulative major adverse cardiovascular events (MACE), MACE plus late revascularization, MI, and all-cause mortality incidence was assessed using the Kaplan-Meier method for persons with no ASCVD history by CAC level and persons with established ASCVD. Cox proportional hazards regression analysis was used to calculate HRs with 95% CIs, which were adjusted for traditional cardiovascular risk factors.
RESULTS: The mean age was 57.6 ± 12.4 years (56% male). In total, 442 of 4,949 (9%) patients experienced MACEs over a median follow-up of 4 years (IQR: 1.7-5.7 years). Incident MACEs increased with higher CAC scores, with the highest rates observed with CAC score >300 and in those with prior ASCVD. All-cause mortality, MACEs, MACE + late revascularization, and MI event rates were not statistically significantly different in those with CAC >300 compared with established ASCVD (all P > 0.05). Persons with a CAC score <300 had substantially lower event rates.
CONCLUSIONS: Patients with CAC scores >300 are at an equivalent risk of MACE and its components as those treated for established ASCVD. This observation, that those with CAC >300 have event rates comparable to those with established ASCVD, supplies important background for further study related to secondary prevention treatment targets in subjects without prior ASCVD with elevated CAC. Understanding the CAC scores that are associated with ASCVD risk equivalent to stable secondary prevention populations may be important for guiding the intensity of preventive approaches more broadly.
引用
- Budoff, Kinninger, Gransar, et al. When Does a Calcium Score Equate to Secondary Prevention?: Insights From the Multinational CONFIRM Registry. JACC Cardiovasc Imaging. 2023. PMID: 37227328. doi:10.1016/j.jcmg.2023.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。